Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis

被引:90
作者
Bao, LH
Osawe, I
Haas, M
Quigg, RJ
机构
[1] Univ Chicago, Nephrol Sect, Chicago, IL 60637 USA
[2] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21287 USA
关键词
D O I
10.4049/jimmunol.175.3.1947
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Signaling of the C3a anaphylatoxin through its G protein-coupled receptor, C3aR, is relevant in a variety of inflammatory diseases, but its role in lupus nephritis is undefined. In this study, we show that expression of C3aR was significantly increased in prediseased and diseased kidneys of MRL/lpr lupus mice compared with MRL/+ controls. To investigate the role of C3aR in experimental lupus, a small molecule antagonist of C3aR (C3aRa) was administered continuously to MRL/lpr mice from 13 to 19 wk of age. All 13 C3aRa-treated mice survived during the 6-wk treatment compared with 9 of 14 (64.3%) control animals given vehicle (p = 0.019). Relative to controls, C3aRa-treated animals were protected from renal disease as measured by albuminuria (P = 0.040) and blood urea nitrogen (p = 0.021). In addition, there were fewer neutrophils, monocytes, and apoptotic cells in the kidneys of C3aRa-treated mice. C3aRa treatment also led to reduced renal IL-1 beta and RANTES mRNA and phosphorylated phosphatase and tensin homologue deleted on chromosome 10 protein, whereas the mass of phosphorylated protein kinase B/Akt was increased by C3aRa. Thus, C3aR antagonism significantly reduces renal disease in MRL/lpr mice, which further translates into prolonged survival. These data illustrate that C3aR is relevant in experimental lupus nephritis and may be a target for therapeutic intervention in the human disease.
引用
收藏
页码:1947 / 1955
页数:9
相关论文
共 74 条
[1]   ABERRANT TRANSCRIPTION CAUSED BY THE INSERTION OF AN EARLY TRANSPOSABLE ELEMENT IN AN INTRON OF THE FAS ANTIGEN GENE OF LPR MICE [J].
ADACHI, M ;
WATANABEFUKUNAGA, R ;
NAGATA, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (05) :1756-1760
[2]   Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models [J].
Ames, RS ;
Lee, D ;
Foley, JJ ;
Jurewicz, AJ ;
Tornetta, MA ;
Bautsch, W ;
Settmacher, B ;
Klos, A ;
Erhard, KF ;
Cousins, RD ;
Sulpizio, AC ;
Hieble, JP ;
McCafferty, G ;
Ward, KW ;
Adams, JL ;
Bondinell, WE ;
Underwood, DC ;
Osborn, RR ;
Badger, AM ;
Sarau, HM .
JOURNAL OF IMMUNOLOGY, 2001, 166 (10) :6341-6348
[3]   SPONTANEOUS MURINE LUPUS-LIKE SYNDROMES - CLINICAL AND IMMUNOPATHOLOGICAL MANIFESTATIONS IN SEVERAL STRAINS [J].
ANDREWS, BS ;
EISENBERG, RA ;
THEOFILOPOULOS, AN ;
IZUI, S ;
WILSON, CB ;
MCCONAHEY, PJ ;
MURPHY, ED ;
ROTHS, JB ;
DIXON, FJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1978, 148 (05) :1198-1215
[4]   Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependenton complement activation [J].
Bao, LH ;
Zhou, R ;
Holers, VM ;
Quigg, RJ .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (10) :2516-2525
[5]   Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice [J].
Bao, LH ;
Haas, M ;
Kraus, DM ;
Hack, BK ;
Rakstang, JK ;
Holers, VM ;
Quigg, RJ .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (03) :670-679
[6]   Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice [J].
Bao, LH ;
Haas, M ;
Boackle, SA ;
Kraus, DM ;
Cunningham, PN ;
Park, P ;
Alexander, JJ ;
Anderson, RK ;
Culhane, K ;
Holers, VM ;
Quigg, RJ .
JOURNAL OF IMMUNOLOGY, 2002, 168 (07) :3601-3607
[7]  
BOSWELL JM, 1988, J IMMUNOL, V141, P3050
[8]  
BOSWELL JM, 1988, J IMMUNOL, V141, P118
[9]   Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies [J].
Botto, M ;
Dell'Agnola, C ;
Bygrave, AE ;
Thompson, EM ;
Cook, HT ;
Petry, F ;
Loos, M ;
Pandolfi, PP ;
Walport, MJ .
NATURE GENETICS, 1998, 19 (01) :56-59
[10]   New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway [J].
Cantley, LC ;
Neel, BG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4240-4245